136 related articles for article (PubMed ID: 9503530)
21. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
Cubrilo-Turek M; Sertić J; Duraković Z
Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
[TBL] [Abstract][Full Text] [Related]
22. [The lipid-protein indices of the blood cholesterol transport system in systemic lupus erythematosus].
Alekberova ZS; Popkova TV; Nasonov EL; Reshetniak TM; Ozerova IN; Perova NV
Ter Arkh; 1999; 71(5):34-8. PubMed ID: 10399228
[TBL] [Abstract][Full Text] [Related]
23. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
24. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
[TBL] [Abstract][Full Text] [Related]
26. [Apoproteins C and E from very low and high density lipoproteins in men with dysalphalipoproteinemia].
Shcherbakova IA; Gerasimova EN; Perova NV; Chernyshova NP
Vopr Med Khim; 1982; 28(3):117-23. PubMed ID: 7101813
[TBL] [Abstract][Full Text] [Related]
27. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
28. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
[TBL] [Abstract][Full Text] [Related]
29. Changes in serum apolipoprotein and lipoprotein profile after alcohol withdrawal: effect of apolipoprotein E polymorphism.
Gueguen S; Herbeth B; Pirollet P; Paille F; Siest G; Visvikis S
Alcohol Clin Exp Res; 2002 Apr; 26(4):501-8. PubMed ID: 11981126
[TBL] [Abstract][Full Text] [Related]
30. Context-dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease: a review.
Frikke-Schmidt R
Scand J Clin Lab Invest Suppl; 2000; 233():3-25. PubMed ID: 11317940
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
32. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas.
Schuler-Lüttmann S; Zhu Y; Hoffmann M; März W; Feussner G; Wieland H; Assmann G; von Eckardstein A
Metabolism; 2000 Jun; 49(6):770-7. PubMed ID: 10877205
[TBL] [Abstract][Full Text] [Related]
34. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
[TBL] [Abstract][Full Text] [Related]
35. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
[TBL] [Abstract][Full Text] [Related]
36. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
37. Brazil nut ingestion increased plasma selenium but had minimal effects on lipids, apolipoproteins, and high-density lipoprotein function in human subjects.
Strunz CC; Oliveira TV; Vinagre JC; Lima A; Cozzolino S; Maranhão RC
Nutr Res; 2008 Mar; 28(3):151-5. PubMed ID: 19083402
[TBL] [Abstract][Full Text] [Related]
38. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia.
Carmena-Ramón R; Real JT; Ascaso JF; Ordovás JM; Carmena R
Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):7-13. PubMed ID: 10812582
[TBL] [Abstract][Full Text] [Related]
39. [Pathogenetic significance of cholesterol-containing immune complexes and lipid peroxidation in ischemic heart disease].
Urazgil'deeva SA; Shatalina LV; Gurevich VS
Ter Arkh; 1999; 71(12):8-10. PubMed ID: 10647190
[TBL] [Abstract][Full Text] [Related]
40. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
